• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病中的免疫细胞及其富含微小RNA的细胞外囊泡:新型治疗靶点

Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets.

作者信息

Yang Liu, Hao Yawen, Boeckmans Joost, Rodrigues Robim M, He Yong

机构信息

Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China.

Department of In Vitro Toxicology and Dermato-Cosmetology, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium.

出版信息

Pharmacol Ther. 2023 Mar;243:108353. doi: 10.1016/j.pharmthera.2023.108353. Epub 2023 Feb 2.

DOI:10.1016/j.pharmthera.2023.108353
PMID:36738973
Abstract

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease worldwide. Despite extensive research and multiple clinical trials, there are still no FDA-approved therapies to treat the most severe forms of NAFLD. This is largely due to its complicated etiology and pathogenesis, which involves visceral obesity, insulin resistance, gut dysbiosis, etc. Although inflammation is generally believed to be one of the critical factors that drive the progression of simple steatosis to nonalcoholic steatohepatitis (NASH), the exact type of inflammation and how it contributes to NASH pathogenesis remain largely unknown. Liver inflammation is accompanied by the elevation of inflammatory mediators, including cytokines and chemokines and consequently intrahepatic infiltration of multiple types of immune cells. Recent studies revealed that extracellular vesicles (EVs) derived from inflammatory cells and hepatocytes play an important role in controlling liver inflammation during NASH. In this review, we highlight the roles of innate and adaptive immune cells and their microRNA-enriched EVs during NAFLD development and discuss potential drugs that target inflammatory pathways for the treatment of NAFLD.

摘要

非酒精性脂肪性肝病(NAFLD)是全球慢性肝病的主要病因。尽管进行了广泛的研究和多项临床试验,但目前仍没有获得美国食品药品监督管理局(FDA)批准的治疗最严重形式NAFLD的疗法。这主要是由于其复杂的病因和发病机制,涉及内脏肥胖、胰岛素抵抗、肠道菌群失调等。虽然炎症通常被认为是推动单纯性脂肪变性发展为非酒精性脂肪性肝炎(NASH)的关键因素之一,但炎症的确切类型及其如何促进NASH发病机制在很大程度上仍不清楚。肝脏炎症伴随着炎症介质的升高,包括细胞因子和趋化因子,进而导致多种类型免疫细胞的肝内浸润。最近的研究表明,源自炎症细胞和肝细胞的细胞外囊泡(EVs)在NASH期间控制肝脏炎症中起重要作用。在这篇综述中,我们强调先天性和适应性免疫细胞及其富含微小RNA的EVs在NAFLD发展过程中的作用,并讨论针对炎症途径治疗NAFLD的潜在药物。

相似文献

1
Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets.非酒精性脂肪性肝病中的免疫细胞及其富含微小RNA的细胞外囊泡:新型治疗靶点
Pharmacol Ther. 2023 Mar;243:108353. doi: 10.1016/j.pharmthera.2023.108353. Epub 2023 Feb 2.
2
MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.微小 RNA 在非酒精性脂肪性肝病发病机制中的作用。
Int J Biol Sci. 2021 Apr 29;17(7):1851-1863. doi: 10.7150/ijbs.59588. eCollection 2021.
3
Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1.肝细胞衍生的细胞外囊泡通过 microRNA-1 促进内皮炎症和动脉粥样硬化形成。
J Hepatol. 2020 Jan;72(1):156-166. doi: 10.1016/j.jhep.2019.09.014. Epub 2019 Sep 27.
4
Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis?细菌和真核细胞外囊泡与非酒精性脂肪性肝病:肠道-肝脏轴的新角色?
Am J Physiol Gastrointest Liver Physiol. 2021 Apr 1;320(4):G485-G495. doi: 10.1152/ajpgi.00362.2020. Epub 2021 Jan 20.
5
Lipotoxic hepatocytes promote nonalcoholic fatty liver disease progression by delivering microRNA-9-5p and activating macrophages.脂毒性肝细胞通过递呈 microRNA-9-5p 并激活巨噬细胞促进非酒精性脂肪性肝病进展。
Int J Biol Sci. 2021 Aug 27;17(14):3745-3759. doi: 10.7150/ijbs.57610. eCollection 2021.
6
Immunological mechanisms and therapeutic targets of fatty liver diseases.脂肪性肝病的免疫机制和治疗靶点。
Cell Mol Immunol. 2021 Jan;18(1):73-91. doi: 10.1038/s41423-020-00579-3. Epub 2020 Dec 2.
7
Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).非酒精性脂肪性肝病(NAFLD)/非酒精性脂肪性肝炎(NASH)的分子机制。
Adv Exp Med Biol. 2021;1261:223-229. doi: 10.1007/978-981-15-7360-6_20.
8
Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223-enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis.中性粒细胞-肝细胞通过 LDLR 依赖性 miR-223 富集的细胞外囊泡转移的通讯改善非酒精性脂肪性肝炎。
J Clin Invest. 2021 Feb 1;131(3). doi: 10.1172/JCI141513.
9
Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH).外泌体 microRNAs 与非酒精性脂肪性肝炎(NASH)的进展。
Int J Mol Sci. 2022 Nov 4;23(21):13501. doi: 10.3390/ijms232113501.
10
Extracellular Vesicles as Inflammatory Drivers in NAFLD.细胞外囊泡作为 NAFLD 的炎症驱动因素。
Front Immunol. 2021 Feb 2;11:627424. doi: 10.3389/fimmu.2020.627424. eCollection 2020.

引用本文的文献

1
Downregulation of ubiquitous microRNA-320 in hepatocytes triggers RFX1-mediated FGF1 suppression to accelerate MASH progression.肝细胞中普遍存在的微小RNA-320的下调触发了RFX1介导的FGF1抑制,从而加速MASH进展。
Acta Pharm Sin B. 2025 Aug;15(8):4096-4114. doi: 10.1016/j.apsb.2025.06.007. Epub 2025 Jun 9.
2
Immunopathogenic mechanisms and immunoregulatory therapies in MASLD.非酒精性脂肪性肝炎的免疫致病机制及免疫调节疗法
Cell Mol Immunol. 2025 Jun 10. doi: 10.1038/s41423-025-01307-5.
3
Inflammation in liver fibrosis and atrial fibrillation: A prospective population-based proteomic study.
肝纤维化与心房颤动中的炎症:一项基于人群的前瞻性蛋白质组学研究。
JHEP Rep. 2024 Jul 18;6(10):101171. doi: 10.1016/j.jhepr.2024.101171. eCollection 2024 Oct.
4
Gut microbiota of miR-30a-5p-deleted mice aggravate high-fat diet-induced hepatic steatosis by regulating arachidonic acid metabolic pathway.miR-30a-5p 缺失小鼠的肠道微生物群通过调节花生四烯酸代谢途径加重高脂肪饮食诱导的肝脂肪变性。
Clin Transl Med. 2024 Oct;14(10):e70035. doi: 10.1002/ctm2.70035.
5
Crosstalk of ubiquitin system and non-coding RNA in fibrosis.泛素系统与非编码RNA在纤维化中的相互作用
Int J Biol Sci. 2024 Jul 8;20(10):3802-3822. doi: 10.7150/ijbs.93644. eCollection 2024.
6
The role of NAD-dependent deacetylase sirtuin-2 in liver metabolic stress through regulating pyruvate kinase M2 ubiquitination.NAD 依赖性去乙酰化酶 Sirtuin-2 通过调节丙酮酸激酶 M2 的泛素化在肝脏代谢应激中的作用。
J Transl Med. 2024 Jul 14;22(1):656. doi: 10.1186/s12967-024-05435-w.
7
Extracellular vesicles: Function, resilience, biomarker, bioengineering, and clinical implications.细胞外囊泡:功能、弹性、生物标志物、生物工程及临床意义
Tzu Chi Med J. 2024 May 24;36(3):251-259. doi: 10.4103/tcmj.tcmj_28_24. eCollection 2024 Jul-Sep.
8
Oxidative stress promotes liver fibrosis by modulating the microRNA-144 and SIN3A-p38 pathways in hepatic stellate cells.氧化应激通过调节肝星状细胞中的 microRNA-144 和 SIN3A-p38 通路促进肝纤维化。
Int J Biol Sci. 2024 Apr 8;20(7):2422-2439. doi: 10.7150/ijbs.92749. eCollection 2024.
9
Liver-derived Exosomal miRNA in NAFLD: Mechanisms of Action, Biomarkers, and Therapeutic Applications.非酒精性脂肪性肝病中肝脏来源的外泌体微小RNA:作用机制、生物标志物及治疗应用
Curr Med Chem. 2024 Jan 30. doi: 10.2174/0109298673276581231210170332.
10
Pharmacogenetics in early drug development for non-alcoholic steatohepatitis: missed chances and future opportunities.非酒精性脂肪性肝炎早期药物研发中的药物遗传学:错失的机会与未来的机遇
Arch Toxicol. 2023 Jun;97(6):1825-1827. doi: 10.1007/s00204-023-03498-0. Epub 2023 May 6.